Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 juin 2010 09h00 HE | Source: Mateon Therapeutics

OXiGENE Reports Encouraging Safety and Efficacy Data from Ongoing Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2010 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 6, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
27 mai 2010 08h00 HE | Source: Mateon Therapeutics

OXiGENE Announces Publication of Preclinical Data on OXi4503 Demonstrating Potent Anti-Leukemic Effects

SOUTH SAN FRANCISCO, Calif., May 27, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
18 mai 2010 16h00 HE | Source: Mateon Therapeutics

OXiGENE Announces Clinical Data to be Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology

SOUTH SAN FRANCISCO, Calif., May 18, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
11 mai 2010 16h17 HE | Source: Mateon Therapeutics

OXiGENE Reports First Quarter 2010 Financial Results

SOUTH SAN FRANCISCO, Calif., May 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
05 mai 2010 08h00 HE | Source: Mateon Therapeutics

OXiGENE Announces First Quarter 2010 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., May 5, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and...
23 avr. 2010 02h00 HE | Source: Mateon Therapeutics

OXiGENE Applies for Voluntary Delisting From the Stockholm Exchange

SOUTH SAN FRANCISCO, Calif., April 23, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
07 avr. 2010 02h00 HE | Source: Mateon Therapeutics

OXiGENE Regains Compliance With NASDAQ Listing Requirements

SOUTH SAN FRANCISCO, Calif., April 7, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
05 avr. 2010 08h00 HE | Source: Mateon Therapeutics

OXiGENE Appoints Tamar D. Howson and Peter J. Langecker to Its Board of Directors

SOUTH SAN FRANCISCO, Calif., April 5, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
19 mars 2010 08h00 HE | Source: Mateon Therapeutics

OXiGENE Announces Going Concern Opinion On Its Audited Financial Statements for 2009

SOUTH SAN FRANCISCO, Calif., March 19, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
15 mars 2010 08h00 HE | Source: Mateon Therapeutics

OXiGENE Announces Change to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 15, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...

Page précédente

Page suivante